Abbott Laboratories

ABT is in a Stage 2 advancing regime with bullish medium-term directional asymmetry driven by a strong Momentum Breakout. Price is extended and at extreme overbought levels, warranting patience. Dividend Growth strategy prefers waiting for pullbacks into the rising 9 and 21 EMAs or the recent breakout zone before engagement.

• ↑Q1 revenue $11.16B (+3.7%), adjusted EPS $1.15 (+6% YoY)
• ↑Exact Sciences acquisition to contribute ~$3B sales in 2026
• ↓Diagnostics segment sales declined 1.5% due to reduced COVID testing